ParameswaranNHariMD

Oncology • Milwaukee, WI

Hematologic Oncology

MCW

Join to view full profile

Dr. Hari is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Hari's full profile

Already have an account?

Office
9200 W Wisconsin Ave
Division Of Neoplastic Diseases
Milwaukee, WI 53226
Phone+1 414-805-6800

Fax+1 414-805-6805
Is this information wrong?

Education & Training

Medical College of Wisconsin Affiliated HospitalsFellowship, Hematology and Medical Oncology, 2002 - 2004
Main Line Health System/Lankenau Medical CenterResidency, Internal Medicine, 1991 - 1994
University of Kerala Medical CollegeClass of 1992

Certifications & Licensure

WI State Medical License 2002 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Acute Myeloid Leukemia T Cell Depletion to Improve Transplants in Adults With Acute Myeloid Leukemia (BMT CTN 0303) Start of enrollment: 2005 Jun 01
Completed
Phase 2
Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer Start of enrollment: 2008 Oct 13
Completed
Phase 1, Phase 2
Stem Cell Related Donor Safety Study Start of enrollment: 2010 Jan 01
Completed
Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702) Start of enrollment: 2010 May 01
Completed
Phase 3
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant Start of enrollment: 2010 Nov 01
Completed
Phase 3
Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma Start of enrollment: 2011 Jul 01
Completed
Phase 1, Phase 2
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) Start of enrollment: 2011 Oct 01
Recruiting
Post-thrombotic Syndrome & Predictors of Recurrence in Catheter-related Thrombosis Start of enrollment: 2014 Jun 01
Completed
Not Applicable
Observational Trial to Evaluate Hematopoietic Stem Cell Transplantation CMV Reactivation Start of enrollment: 2015 Jun 01
Completed
Study of Bendamustine and IXAZOMIB (MLN9708) Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma Start of enrollment: 2015 Oct 09
Completed
Phase 1, Phase 2
Pharmacokinetic Study of Propylene Glycol-Free Melphalan HCl for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation Start of enrollment: 2016 Nov 01
Completed
Phase 2
Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries With Multiple Myeloma Start of enrollment: 2017 Jul 25
Recruiting
Tinostamustine Conditioning and Autologous Stem Cell Start of enrollment: 2018 Oct 15
Terminated
Phase 1, Phase 2
Gene Therapy Trial for Platelet Derived Factor VIII Production in Hemophilia A Start of enrollment: 2020 Apr 29
Recruiting
Phase 1
S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration Start of enrollment: 2019 Aug 13
Recruiting
Phase 3
Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL) Start of enrollment: 2019 Sep 23
Active, not recruiting
Phase 1
A Study of WVT078 in Patients With Multiple Myeloma (MM) Start of enrollment: 2019 Dec 05
Active, not recruiting
Phase 1
Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma Start of enrollment: 2020 Nov 30
Completed
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

Enhancing prognostic power in multiple myeloma using a plasma cell signature derived from single-cell RNA sequencing.
Jian-Rong Li, Shahram Arsang-Jang, Yan Cheng, Fumou Sun, Anita D'Souza, Binod Dhakal, Parameswaran Hari, Quillan Huang, Paul Auer, Yong Li, Raul Urrutia, Fenghuang Zha...> ;Blood Cancer Journal. 2024 Mar 6
Impact of Visceral Obesity on Clinical Outcome and Quality of Life for Patients with Multiple Myeloma: A Secondary Data Analysis of STaMINA (BMT CTN 0702) Trial.
Fu, P., Li, G., Malek, E., Kort, J., Metheny, L., Hari, P., Efebera, Y., Callander, N., Qazilbash, M., Giralt, S., Krishnan, A., Stadtmauer, E., Lazarus, H.> ;Transplantation and Cellular Therapy. 2024 Jan 19
Identification of novel loci for multiple myeloma when comparing with its precursor condition monoclonal gammopathy of unknown significance.
Christopher Staffi Buradagunta, Shahram Arsang-Jang, Ben Massat, Bicky Thapa, Anita D'Souza, Paul Auer, Raul Urrutia, Siegfried Janz, Binod Dhakal, Parameswaran Hari, ...> ;Leukemia. 2024 Feb 1
4 citations
Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial.
Costa, L., Chhabra, S., Medvedova, E., Dholaria, B., Schmidt, T., Godby, K., Silbermann, R., Dhakal, B., Bal, S., Giri, S., D'Souza, A., Hall, A., Hardwick, P., Omel, ...> ;The Lancet. Haematology. 2023 Nov 1
Impact of Visceral Obesity on Clinical Outcome and Quality of Life for Patients with Multiple Myeloma: A Secondary Data Analysis of STaMINA (BMT CTN 0702) Trial.
Ehsan Malek, Jeries Kort, Leland Metheny, Pingfu Fu, Parameswaran Hari, Gen Li, Yvonne Efebera, Natalie Callander, Muzaffar Qazilbash, Sergio Giralt, Amrita Krishnan, ...> ;Research Square. 2023 Sep 21
1 citations
Impact of Baseline and Week 2 and Week 4 Posttransplant CMV Cell-Mediated Immunity on Risk of CMV Infections and Mortality in Recipients of Allogeneic Hematopoietic Ce...
Ella J Ariza-Heredia, Drew J Winston, Scott D Rowley, Kathleen Mullane, Pranatharthi Chandrasekar, Parameswaran Hari, Robin K Avery, Karl S Peggs, Deepali Kumar, Rajne...> ;Open Forum Infectious Diseases. 2023 Aug 1
4 citations
Protracted viral infections in patients with multiple myeloma receiving bispecific T-cell engager therapy targeting B-cell maturation antigen.
Breanna Palmen, Parameswaran Hari, Anita D'Souza, Muhammad Bilal Abid> ;Haematologica. 2023 Nov 1
2 citations
A timeline of genetic variant enrichment: from multiple myeloma diagnosis to myeloma-associated myeloid malignancy.
Ariel Kleman, Arun Singavi, Lauren Pommert, Angela J Mathison, Parameswaran Hari, Binod Dhakal, Meera Mohan, Siegfried Janz, Jennifer M Knight, Mithun V Shah, Carolina...> ;Blood Advances. 2023 Sep 26
Efficacy, safety, and cost of mobilization strategies in multiple myeloma: a prospective, observational study.
Binod Dhakal, Mei-Jei Zhang, Linda J Burns, Xiaoying Tang, Christa Meyer, Lih-Wen Mau, Ajay K Nooka, Edward Stadtmauer, Ivana N Micallef, Joseph McGuirk, Luciano Costa...> ;Haematologica. 2023 Aug 1
3 citations
Patient Perceptions Regarding Ciltacabtagene Autoleucel Treatment: Qualitative Evidence From Interviews With Patients With Relapsed/Refractory Multiple Myeloma in the ...
Adam D Cohen, Parameswaran Hari, Myo Htut, Jesus G Berdeja, Saad Z Usmani, Deepu Madduri, Yunsi Olyslager, Jenna D Goldberg, Jordan M Schecter, Carolyn C Jackson, Kath...> ;Clinical Lymphoma, Myeloma & Leukemia. 2023 Jan 1
2 citations
Mitigation of gastrointestinal graft--host disease with tocilizumab prophylaxis is accompanied by preservation of microbial diversity and attenuation of enterococcal d...
Saurabh Chhabra, Aniko Szabo, Annelie Clurman, Katelynn McShane, Nicholas Waters, Daniel Eastwood, Lisa Samanas, Teng Fei, Gabriel Armijo, Sameen Abedin, Walter Longo,...> ;Haematologica. 2023 Jan 1
10 citations
Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b-2, open-label study.
Thomas Martin, Yi Lin, Mounzer Agha, Adam D Cohen, Myo Htut, A Keith Stewart, Parameswaran Hari, Jesus G Berdeja, Saad Z Usmani, Tzu-Min Yeh, Yunsi Olyslager, Jenna D ...> ;The Lancet. Haematology. 2022 Dec 1
1 citations
Exploring health behaviors and the feasibility of a lifestyle intervention for patients with multiple myeloma.
Allen Hodge, Patricia Sheean, Paula O'Connor, Kiley Tyler, Abigail Kerschner, Alexis Williams, Kathleen Jensik, Alexis Visotcky, Anita D'Souza, Parameswaran Hari, Bino...> ;Supportive Care in Cancer. 2022 Dec 1
2 citations
Exercise "CALM" and make CAR-T therapy work better.
Heng Mei, Parameswaran Hari, Yu Hu> ;Science Bulletin. 2022 Oct 15
Corrigendum to 'Ixazomib for chronic Graft-Versus-Host Disease prophylaxis following allogeneic hematopoietic cell transplantation' [Biology of Blood and Marrow Transp...
Saurabh Chhabra, Alexis Visotcky, Marcelo C Pasquini, Fenlu Zhu, Xiaoying Tang, Mei-Jie Zhang, Robert Thompson, Sameem Abedin, Anita D'Souza, Binod Dhakal, William R D...> ;Transplantation and Cellular Therapy. 2022 Oct 1
1 citations
Corrigendum to 'Current Use and Trends in Hematopoietic Cell Transplantation in the United States' [Transplantation and Cellular Therapy 26/8 (2020) e177-e182].
Anita D'Souza, Caitrin Fretham, Stephanie J Lee, Mukta Arora, Janet Brunner, Saurabh Chhabra, Steven Devine, Mary Eapen, Mehdi Hamadani, Parameswaran Hari, Marcelo C P...> ;Transplantation and Cellular Therapy. 2022 Oct 1
3 citations
Meta-analysis of ciltacabtagene autoleucel versus physician's choice therapy for the treatment of patients with relapsed or refractory multiple myeloma.
Luciano J Costa, Parameswaran Hari, Jesus G Berdeja, Valerio De Stefano, Francesca Gay, Becky Hooper, Meaghan Bartlett, Anja Haltner, Emily Rosta, Shaji Kumar, Thomas ...> ;Current Medical Research and Opinion. 2022 Oct 1
5 citations
Long-term outcomes and predictors of early response, late relapse, and survival for patients treated with bispecific LV20.19 CAR T-cells.
Joanna C Zurko, Timothy S Fenske, Bryon D Johnson, Daniel Bucklan, Aniko Szabo, Huiqing Xu, Katherine Chaney, Mehdi Hamadani, Parameswaran Hari, Nirav N Shah> ;American Journal of Hematology. 2022 Dec 1
98 citations
Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma.
Costa, L., Chhabra, S., Medvedova, E., Dholaria, B., Schmidt, T., Godby, K., Silbermann, R., Dhakal, B., Bal, S., Giri, S., D'Souza, A., Hall, A., Hardwick, P., Omel, ...> ;Journal of Clinical Oncology. 2022 Sep 1
14 citations
FOXM1 regulates glycolysis and energy production in multiple myeloma.
Yan Cheng, Fumou Sun, Krista Thornton, Xuefang Jing, Jing Dong, Grant Yun, Michael Pisano, Fenghuang Zhan, Sung Hoon Kim, John A Katzenellenbogen, Benita S Katzenellen...> ;Oncogene. 2022 Aug 1
2 citations
A Multicenter Phase II, Double-Blind, Placebo-Controlled Trial of Maintenance Ixazomib After Allogeneic Transplantation for High-Risk Multiple Myeloma: Results of the ...
Qaiser Bashir, Taiga Nishihori, Marcelo C Pasquini, Michael J Martens, Juan Wu, Melissa Alsina, Claudio Anasetti, Claudio Brunstein, Peter Dawson, Yvonne Efebera, Cris...> ;Transplantation and Cellular Therapy. 2023 Jun 1
7 citations
Indirect treatment comparison of idecabtagene vicleucel versus conventional care in triple-class exposed multiple myeloma.
Nina Shah, Ali Mojebi, Dieter Ayers, Shannon Cope, Sujith Dhanasiri, Faith E Davies, Parameswaran Hari, Payal Patel, Kristen Hege, Devender Dhanda> ;Journal of Comparative Effectiveness Research. 2022 Jul 1
2 citations
Shorter Interval between Treatment and COVID Immunization Is Associated With Poor Seroconversion in Patients with Hematological Malignancies.
Meera Mohan, Sneha Nagavally, Nirav N Shah N, Laura Michaelis, Saurabh Chhabra, Anita D Souza, Sameem Abedin, Lyndsey Runaas, Guru Subramanian Guru Murthy, Walter Long...> ;Clinical Lymphoma, Myeloma & Leukemia. 2022 Jul 1
7 citations
Patient perspectives on symptoms, health-related quality of life, and treatment experience associated with relapsed/refractory multiple myeloma.
Nitya Nathwani, Jill Bell, Dasha Cherepanov, France Ginchereau Sowell, Rachel Shah, Kelly McCarrier, Parameswaran Hari> ;Supportive Care in Cancer. 2022 Jul 1
139 citations
Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Fol...
Thomas Martin, Saad Z Usmani, Jesus G Berdeja, Mounzer Agha, Adam D Cohen, Parameswaran Hari, David Avigan, Abhinav Deol, Myo Htut, Alexander Lesokhin, Nikhil C Munshi...> ;Journal of Clinical Oncology. 2023 Feb 20
Join now to see all

Journal Articles

Related Peripheral Blood Stem Cell Donors Experience More Severe Symptoms and Less Complete Recovery at 1-Year Compared to Unrelated Donors
Parameswaran N Hari, David A Jacobsohn, Joseph P McGuirk, Mary M Horowitz, Walter Longo, Thomas Spitzer, Daniel J Weisdorf, Shahram Mori, David C Delgado, Marcie L Ric..., Haematologica
Long Term Follow-up of Tandem Autologous-Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma
Parameswaran Hari, Brenda M Sandmaier, Pamela S Becker, Leona Holmberg, Damian J Green, Peter A McSweeney, David G Maloney, Thomas R Chauncey, Haematologica
Second Primary Malignancy After Multiple Myeloma‐Population Trends and Cause‐Specific Mortality
Parameswaran Hari, Luciano J Costa, Saurabh Chhabra, Kelly N Godby, British Journal of Haematology
Final Outcomes of Escalated Melphalan 280 mg/m2 with Amifostine Cytoprotection Followed Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma: High C...
Neal Flomenberg, Dianna S Howard, Barry R Meisenberg, Parameswaran Hari, Gordon L Phillips, David H Vesole, Jasleen Randhawa, Aaron P Rapoport, Nature
Join now to see all

Abstracts/Posters

Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined An...
Parameswaran Hari, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Phase I Clinical Trial of CK0801 (cord blood regulatory T cells) in Patients with Bone Marrow Failure Syndrome (BMF) Including Aplastic Anemia, Myelodysplasia and Myel...
Parameswaran Hari, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined An...
Parameswaran Hari, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Evolving Real-World Treatment Patterns in Patients with Newly-Diagnosed Multiple Myeloma (NDMM) in the United States (U.S.)
Parameswaran Hari, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) Induction, Autologous Transplantation and Post-Transplant, Response-Adapted, Measurable Residual Di...
Parameswaran Hari, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Preliminary Results from a Phase 1b Study of TAK-079, an Investigational Anti-CD38 Monoclonal Antibody (mAb) in Patients with Relapsed/ Refractory Multiple Myeloma (RRMM)
Parameswaran Hari, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Primary Plasma Cell Leukemia Outcomes Remain Dismal Despite Novel Agents and Hematopoietic Cell Transplantation
Parameswaran Hari, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Fresh Versus Cryopreserved/Thawed Bispecific Anti-CD19/CD20 CAR-T Cells for Relapsed, Refractory Non-Hodgkin Lymphoma
Parameswaran Hari, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Busulfan, Melphalan, and Bortezomib Compared to Single Agent High-Dose Melphalan As a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Mu...
Parameswaran Hari, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Novel Prognostic Scoring System for Autologous Hematopoietic Cell Transplantation (AHCT) in Multiple Myeloma (MM)
Parameswaran Hari, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Tandem Autologous-Autologous Vs. Autologous-Allogeneic Transplantation for Newly Diagnosed Multiple Myeloma: Pooled Analysis of 1,338 Patients from Four Trials with Lo...
Parameswaran Hari, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Versican (VCAN) Proteolysis Predicts Survival in Multiple Myeloma (MM) after High Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT/AHCT)
Parameswaran Hari, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Results of a Phase I Study of Pnk-007, Allogeneic, Off the Shelf NK Cell, Post Autologous Transplant in Multiple Myeloma (NCT02955550)
Parameswaran Hari, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Breaking the Glass Ceiling of Age in Transplant in Multiple Myeloma
Parameswaran Hari, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

A 3D Learning Experience: Novel Combination Treatment Options and Sequencing Strategies for Personalized Management of Relapsed and/or Refractory Multiple Myeloma
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Prospective study to measure the impact of MMprofiler on treatment intention in newly diagnosed multiple myeloma patients (PROMMIS).
2019 ASCO Annual Meeting - 6/1/2019
Subsequent Treatment Outcomes of Multiple Myeloma Refractory to CD38-Monoclonal Antibody Therapy
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Adjuvant Doxycycline to Enhance Anti-Amyloid Effects: Results from the DUAL (Doxycycline to Upgrade response in AL amyloidosis) Study
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
A Phase 1 Study of Two Investigational Agents, ACTR087, an Autologous T Cell Product Expressing an Antibody-Coupled T Cell Receptor, in Combination with SEA-BCMA, a No...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Phase I/II Trial of Bendamustine, Ixazomib and Dexamethasone (BID) in Patients (pts.) with Relapsed/Refractory Multiple Myeloma (RRMM)
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Join now to see all

Press Mentions

New FDA Approved Drug for Multiple MyelomaMarch 25th, 2021
Hem/Onc Roundup: Financial Toxicity in MM Treatment, Personalizing Cancer Care, and MoreFebruary 19th, 2021
Dr. Hari Discusses Upfront AHCT for Multiple MyelomaFebruary 17th, 2021
Join now to see all